APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Immuno-oncology Drugs

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Immuno-oncology Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

Report ID 174002040322 December 2025190 pages

Choose your research edition.

Industry ResearchImmuno-oncology Drugs Industry Research Report 2026141 pages · $2,950 USDIndustry Growth & TrendsGlobal Immuno-oncology Drugs Industry Growth and Trends Forecast to 2032123 pages · $3,450 USDMarket StructureGlobal Immuno-oncology Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032190 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Immuno-oncology Drugs Market Outlook and Growth Opportunities 2026218 pages · $4,250 USDMarket Analysis & ForecastGlobal Immuno-oncology Drugs Market Analysis and Forecast 2026-2032215 pages · $4,950 USD

Market perspective

The global Immuno-oncology Drugs market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The US & Canada market for Immuno-oncology Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Immuno-oncology Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Immuno-oncology Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Immuno-oncology Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Immuno-oncology Drugs include Sanofi S.A., Johnson & Johnson, Merck & Co., Lonza Group, Eli Lilly and Company, Pfizer Inc., Ferring Pharmaceuticals, Amgen, Inc and AbbVie, Inc., among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Includes

This report provides an overview of the global Immuno-oncology Drugs market and its size, analyzing global market trends based on historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Immuno-oncology Drugs and revenue in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Immuno-oncology Drugs revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering revenue and growth rates—for 2021-2032, and evaluates and forecasts the Immuno-oncology Drugs market size, projected growth trends, production technologies, key applications, and end-use industries.

Immuno-oncology Drugs Segment by Company

Sanofi S.A.

Johnson & Johnson

Merck & Co.

Lonza Group

Eli Lilly and Company

Pfizer Inc.

Ferring Pharmaceuticals

Amgen, Inc

AbbVie, Inc.

AstraZeneca, Plc

Spring Bank Pharmaceuticals, Inc.

Prometheus Therapeutics & Diagnostics

Novartis International AG

Incyte

ImmunoCellular Therapeutics

Hoffmann-La Roche AG

Gilead Sciences Inc.

Galena Biopharma

Enzo Biochem, Inc.

EMD Serono, Inc.

Dendreon Corporation

Celldex Therapeutics

Celgene Corporation

Bristol-Myers Squibb

Bio-Rad Laboratories, Inc.

Bavarian Nordic

Avantor, Inc.

Agilent Technologies Inc.

Agenus Inc.

Aduro BioTech

Immuno-oncology Drugs Segment by Type

Oncolytic Virus

Immune System Modulators

Immune Checkpoint Inhibitors

Cancer Vaccines

Others

Immuno-oncology Drugs Segment by Application

Clinics

Hospitals

Community Centers

Immuno-oncology Drugs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Immuno-oncology Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Immuno-oncology Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Immuno-oncology Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. Revenue of Immuno-oncology Drugs in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Immuno-oncology Drugs industry.

Chapter 3: Detailed analysis of Immuno-oncology Drugs companies' competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Immuno-oncology Drugsrevenue, gross margin, and recent development, etc.

Chapter 7: North America (US & Canada) by type, by application and by country, revenue for each segment.

Chapter 8: Europe by type, by application and by country, revenue for each segment.

Chapter 9: China by type, and by application, revenue for each segment.

Chapter 10: Asia (excluding China) by type, by application and by region, revenue for each segment.

Chapter 11: South America, Middle East & Africa by type, by application and by country, revenue for each segment.

Chapter 12: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Immuno-oncology Drugs Market Size Growth Rate by Type (US$ Million): 2021 VS 2025 VS 2032 Table 2. Key Players of Oncolytic Virus Table 3. Key Players of Immune System Modulators Table 4. Key Players of Immune Checkpoint Inhibitors Table 3. Key Players of Cancer Vaccines Table 4. Key Players of Others Table 5. Global Immuno-oncology Drugs Market Size Growth Rate by Application (US$ Million): 2021 VS 2025 VS 2032 Table 6. Key Players of Clinics Table 7. Key Players of Hospitals Table 8. Key Players of Community Centers Table 9. Global Immuno-oncology Drugs Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 10. Global Immuno-oncology Drugs Market Size by Region (2021-2026) & (US$ Million) Table 11. Global Immuno-oncology Drugs Market Share by Region (2021-2026) Table 12. Global Immuno-oncology Drugs Market Size by Region (2027-2032) & (US$ Million) Table 13. Global Immuno-oncology Drugs Market Share by Region (2027-2032) Table 14. Immuno-oncology Drugs Industry Trends Table 15. Immuno-oncology Drugs Industry Drivers Table 16. Immuno-oncology Drugs Industry Opportunities and Challenges Table 17. Immuno-oncology Drugs Industry Restraints Table 18. Global Immuno-oncology Drugs Revenue by Company (US$ Million) & (2021-2026) Table 19. Global Immuno-oncology Drugs Revenue Market Share by Company (2021-2026) Table 20. Global Immuno-oncology Drugs Players Revenue Ranking, 2024 VS 2025 VS 2026 Table 21. Global Immuno-oncology Drugs Key Company Head Office and Area Served Table 22. Global Immuno-oncology Drugs Company, Product Type & Application Table 23. Global Immuno-oncology Drugs Company Establishment Date Table 24. Global Company Market Concentration Ratio (CR5 and HHI) Table 25. Global Immuno-oncology Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 26. Global Immuno-oncology Drugs Market Size by Type 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Immuno-oncology Drugs Market Size by Type (2021-2026) & (US$ Million) Table 28. Global Immuno-oncology Drugs Market Size by Type (2027-2032) & (US$ Million) Table 29. Global Immuno-oncology Drugs Revenue Market Share by Type (2021-2026) Table 30. Global Immuno-oncology Drugs Revenue Market Share by Type (2027-2032) Table 31. Global Immuno-oncology Drugs Market Size by Application 2021 VS 2025 VS 2032 (US$ Million) Table 32. Global Immuno-oncology Drugs Market Size by Application (2021-2026) & (US$ Million) Table 33. Global Immuno-oncology Drugs Market Size by Application (2027-2032) & (US$ Million) Table 34. Global Immuno-oncology Drugs Revenue Market Share by Application (2021-2026) Table 35. Global Immuno-oncology Drugs Revenue Market Share by Application (2027-2032) Table 36. Sanofi S.A. Company Information Table 37. Sanofi S.A. Business Overview Table 38. Sanofi S.A. Immuno-oncology Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 39. Sanofi S.A. Immuno-oncology Drugs Product Portfolio Table 40. Sanofi S.A. Recent Development Table 41. Johnson & Johnson Company Information Table 42. Johnson & Johnson Business Overview Table 43. Johnson & Johnson Immuno-oncology Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 44. Johnson & Johnson Immuno-oncology Drugs Product Portfolio Table 45. Johnson & Johnson Recent Development Table 46. Merck & Co. Company Information Table 47. Merck & Co. Business Overview Table 48. Merck & Co. Immuno-oncology Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 49. Merck & Co. Immuno-oncology Drugs Product Portfolio Table 50. Merck & Co. Recent Development Table 51. Lonza Group Company Information Table 52. Lonza Group Business Overview Table 53. Lonza Group Immuno-oncology Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 54. Lonza Group Immuno-oncology Drugs Product Portfolio Table 55. Lonza Group Recent Development Table 56. Eli Lilly and Company Company Information Table 57. Eli Lilly and Company Business Overview Table 58. Eli Lilly and Company Immuno-oncology Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 59. Eli Lilly and Company Immuno-oncology Drugs Product Portfolio Table 60. Eli Lilly and Company Recent Development Table 61. Pfizer Inc. Company Information Table 62. Pfizer Inc. Business Overview Table 63. Pfizer Inc. Immuno-oncology Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 64. Pfizer Inc. Immuno-oncology Drugs Product Portfolio Table 65. Pfizer Inc. Recent Development Table 66. Ferring Pharmaceuticals Company Information Table 67. Ferring Pharmaceuticals Business Overview Table 68. Ferring Pharmaceuticals Immuno-oncology Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 69. Ferring Pharmaceuticals Immuno-oncology Drugs Product Portfolio Table 70. Ferring Pharmaceuticals Recent Development Table 71. Amgen, Inc Company Information Table 72. Amgen, Inc Business Overview Table 73. Amgen, Inc Immuno-oncology Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 74. Amgen, Inc Immuno-oncology Drugs Product Portfolio Table 75. Amgen, Inc Recent Development Table 76. AbbVie, Inc. Company Information Table 77. AbbVie, Inc. Business Overview Table 78. AbbVie, Inc. Immuno-oncology Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 79. AbbVie, Inc. Immuno-oncology Drugs Product Portfolio Table 80. AbbVie, Inc. Recent Development Table 81. AstraZeneca, Plc Company Information Table 82. AstraZeneca, Plc Business Overview Table 83. AstraZeneca, Plc Immuno-oncology Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 84. AstraZeneca, Plc Immuno-oncology Drugs Product Portfolio Table 85. AstraZeneca, Plc Recent Development Table 86. Spring Bank Pharmaceuticals, Inc. Company Information Table 87. Spring Bank Pharmaceuticals, Inc. Business Overview Table 88. Spring Bank Pharmaceuticals, Inc. Immuno-oncology Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 89. Spring Bank Pharmaceuticals, Inc. Immuno-oncology Drugs Product Portfolio Table 90. Spring Bank Pharmaceuticals, Inc. Recent Development Table 91. Prometheus Therapeutics & Diagnostics Company Information Table 92. Prometheus Therapeutics & Diagnostics Business Overview Table 93. Prometheus Therapeutics & Diagnostics Immuno-oncology Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 94. Prometheus Therapeutics & Diagnostics Immuno-oncology Drugs Product Portfolio Table 95. Prometheus Therapeutics & Diagnostics Recent Development Table 96. Novartis International AG Company Information Table 97. Novartis International AG Business Overview Table 98. Novartis International AG Immuno-oncology Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 99. Novartis International AG Immuno-oncology Drugs Product Portfolio Table 100. Novartis International AG Recent Development Table 101. Incyte Company Information Table 102. Incyte Business Overview Table 103. Incyte Immuno-oncology Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 104. Incyte Immuno-oncology Drugs Product Portfolio Table 105. Incyte Recent Development Table 106. ImmunoCellular Therapeutics Company Information Table 107. ImmunoCellular Therapeutics Business Overview Table 108. ImmunoCellular Therapeutics Immuno-oncology Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 109. ImmunoCellular Therapeutics Immuno-oncology Drugs Product Portfolio Table 110. ImmunoCellular Therapeutics Recent Development Table 111. Hoffmann-La Roche AG Company Information Table 112. Hoffmann-La Roche AG Business Overview Table 113. Hoffmann-La Roche AG Immuno-oncology Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 114. Hoffmann-La Roche AG Immuno-oncology Drugs Product Portfolio Table 115. Hoffmann-La Roche AG Recent Development Table 116. Gilead Sciences Inc. Company Information Table 117. Gilead Sciences Inc. Business Overview Table 118. Gilead Sciences Inc. Immuno-oncology Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 119. Gilead Sciences Inc. Immuno-oncology Drugs Product Portfolio Table 120. Gilead Sciences Inc. Recent Development Table 121. Galena Biopharma Company Information Table 122. Galena Biopharma Business Overview Table 123. Galena Biopharma Immuno-oncology Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 124. Galena Biopharma Immuno-oncology Drugs Product Portfolio Table 125. Galena Biopharma Recent Development Table 126. Enzo Biochem, Inc. Company Information Table 127. Enzo Biochem, Inc. Business Overview Table 128. Enzo Biochem, Inc. Immuno-oncology Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 129. Enzo Biochem, Inc. Immuno-oncology Drugs Product Portfolio Table 130. Enzo Biochem, Inc. Recent Development Table 131. EMD Serono, Inc. Company Information Table 132. EMD Serono, Inc. Business Overview Table 133. EMD Serono, Inc. Immuno-oncology Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 134. EMD Serono, Inc. Immuno-oncology Drugs Product Portfolio Table 135. EMD Serono, Inc. Recent Development Table 136. Dendreon Corporation Company Information Table 137. Dendreon Corporation Business Overview Table 138. Dendreon Corporation Immuno-oncology Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 139. Dendreon Corporation Immuno-oncology Drugs Product Portfolio Table 140. Dendreon Corporation Recent Development Table 141. Celldex Therapeutics Company Information Table 142. Celldex Therapeutics Business Overview Table 143. Celldex Therapeutics Immuno-oncology Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 144. Celldex Therapeutics Immuno-oncology Drugs Product Portfolio Table 145. Celldex Therapeutics Recent Development Table 146. Celgene Corporation Company Information Table 147. Celgene Corporation Business Overview Table 148. Celgene Corporation Immuno-oncology Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 149. Celgene Corporation Immuno-oncology Drugs Product Portfolio Table 150. Celgene Corporation Recent Development Table 151. Bristol-Myers Squibb Company Information Table 152. Bristol-Myers Squibb Business Overview Table 153. Bristol-Myers Squibb Immuno-oncology Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 154. Bristol-Myers Squibb Immuno-oncology Drugs Product Portfolio Table 155. Bristol-Myers Squibb Recent Development Table 156. Bio-Rad Laboratories, Inc. Company Information Table 157. Bio-Rad Laboratories, Inc. Business Overview Table 158. Bio-Rad Laboratories, Inc. Immuno-oncology Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 159. Bio-Rad Laboratories, Inc. Immuno-oncology Drugs Product Portfolio Table 160. Bio-Rad Laboratories, Inc. Recent Development Table 161. Bavarian Nordic Company Information Table 162. Bavarian Nordic Business Overview Table 163. Bavarian Nordic Immuno-oncology Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 164. Bavarian Nordic Immuno-oncology Drugs Product Portfolio Table 165. Bavarian Nordic Recent Development Table 166. Avantor, Inc. Company Information Table 167. Avantor, Inc. Business Overview Table 168. Avantor, Inc. Immuno-oncology Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 169. Avantor, Inc. Immuno-oncology Drugs Product Portfolio Table 170. Avantor, Inc. Recent Development Table 171. Agilent Technologies Inc. Company Information Table 172. Agilent Technologies Inc. Business Overview Table 173. Agilent Technologies Inc. Immuno-oncology Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 174. Agilent Technologies Inc. Immuno-oncology Drugs Product Portfolio Table 175. Agilent Technologies Inc. Recent Development Table 176. Agenus Inc. Company Information Table 177. Agenus Inc. Business Overview Table 178. Agenus Inc. Immuno-oncology Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 179. Agenus Inc. Immuno-oncology Drugs Product Portfolio Table 180. Agenus Inc. Recent Development Table 181. Aduro BioTech Company Information Table 182. Aduro BioTech Business Overview Table 183. Aduro BioTech Immuno-oncology Drugs Revenue and Gross Margin (US$ Million) & (2021-2026) Table 184. Aduro BioTech Immuno-oncology Drugs Product Portfolio Table 185. Aduro BioTech Recent Development Table 186. North America Immuno-oncology Drugs Market Size by Type (2021-2026) & (US$ Million) Table 187. North America Immuno-oncology Drugs Market Size by Type (2027-2032) & (US$ Million) Table 188. North America Immuno-oncology Drugs Market Size by Application (2021-2026) & (US$ Million) Table 189. North America Immuno-oncology Drugs Market Size by Application (2027-2032) & (US$ Million) Table 190. North America Immuno-oncology Drugs Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 191. North America Immuno-oncology Drugs Market Size by Country (2021-2026) Table 192. North America Immuno-oncology Drugs Market Size by Country (2027-2032) Table 193. Europe Immuno-oncology Drugs Market Size by Type (2021-2026) & (US$ Million) Table 194. Europe Immuno-oncology Drugs Market Size by Type (2027-2032) & (US$ Million) Table 195. Europe Immuno-oncology Drugs Market Size by Application (2021-2026) & (US$ Million) Table 196. Europe Immuno-oncology Drugs Market Size by Application (2027-2032) & (US$ Million) Table 197. Europe Immuno-oncology Drugs Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 198. Europe Immuno-oncology Drugs Market Size by Country (2021-2026) Table 199. Europe Immuno-oncology Drugs Market Size by Country (2027-2032) Table 200. China Immuno-oncology Drugs Market Size by Type (2021-2026) & (US$ Million) Table 201. China Immuno-oncology Drugs Market Size by Type (2027-2032) & (US$ Million) Table 202. China Immuno-oncology Drugs Market Size by Application (2021-2026) & (US$ Million) Table 203. China Immuno-oncology Drugs Market Size by Application (2027-2032) & (US$ Million) Table 204. Asia Immuno-oncology Drugs Market Size by Type (2021-2026) & (US$ Million) Table 205. Asia Immuno-oncology Drugs Market Size by Type (2027-2032) & (US$ Million) Table 206. Asia Immuno-oncology Drugs Market Size by Application (2021-2026) & (US$ Million) Table 207. Asia Immuno-oncology Drugs Market Size by Application (2027-2032) & (US$ Million) Table 208. Asia Immuno-oncology Drugs Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 209. Asia Immuno-oncology Drugs Market Size by Country (2021-2026) Table 210. Asia Immuno-oncology Drugs Market Size by Country (2027-2032) Table 211. South America, Middle East & Africa Immuno-oncology Drugs Market Size by Type (2021-2026) & (US$ Million) Table 212. South America, Middle East & Africa Immuno-oncology Drugs Market Size by Type (2027-2032) & (US$ Million) Table 213. South America, Middle East & Africa Immuno-oncology Drugs Market Size by Application (2021-2026) & (US$ Million) Table 214. South America, Middle East & Africa Immuno-oncology Drugs Market Size by Application (2027-2032) & (US$ Million) Table 215. South America, Middle East & Africa Immuno-oncology Drugs Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 216. South America, Middle East & Africa Immuno-oncology Drugs Market Size by Country (2021-2026) Table 217. South America, Middle East & Africa Immuno-oncology Drugs Market Size by Country (2027-2032) Table 218. Research Programs/Design for This Report Table 219. Authors List of This Report Table 220. Secondary Sources Table 221. Primary Sources List of Figures Figure 1. Immuno-oncology Drugs Product Image Figure 2. Global Immuno-oncology Drugs Market Size Growth Rate by Type, 2021 VS 2025 VS 2032 (US$ Million) Figure 3. Global Immuno-oncology Drugs Market Share by Type: 2025 VS 2032 Figure 4. Oncolytic Virus Image Figure 5. Immune System Modulators Image Figure 6. Immune Checkpoint Inhibitors Image Figure 7. Cancer Vaccines Image Figure 8. Others Image Figure 9. Global Immuno-oncology Drugs Market Size Growth Rate by Application, 2021 VS 2025 VS 2032 (US$ Million) Figure 10. Global Immuno-oncology Drugs Market Share by Application: 2025 VS 2032 Figure 11. Clinics Image Figure 12. Hospitals Image Figure 13. Community Centers Image Figure 14. Global Immuno-oncology Drugs Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 15. Global Immuno-oncology Drugs Market Size (2021-2032) & (US$ Million) Figure 16. Global Immuno-oncology Drugs Market Share by Region: 2025 VS 2032 Figure 17. Years Considered Figure 18. Global Immuno-oncology Drugs Market Share by Players in 2025 Figure 19. Global Top 5 and 10 Immuno-oncology Drugs Players Market Share by Revenue in 2025 Figure 20. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 21. Global Immuno-oncology Drugs Market Size by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 22. Global Immuno-oncology Drugs Revenue Market Share by Type (2021-2032) Figure 23. Global Immuno-oncology Drugs Market Size by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 24. Global Immuno-oncology Drugs Revenue Market Share by Application (2021-2032) Figure 25. North America Immuno-oncology Drugs Market Size (2021-2032) & (US$ Million) Figure 26. North America Immuno-oncology Drugs Market Share by Type (2021-2032) Figure 27. North America Immuno-oncology Drugs Market Share by Application (2021-2032) Figure 28. North America Immuno-oncology Drugs Market Share by Country (2021-2032) Figure 29. United States Immuno-oncology Drugs Market Size (2021-2032) & (US$ Million) Figure 30. Canada Immuno-oncology Drugs Market Size (2021-2032) & (US$ Million) Figure 31. Mexico Immuno-oncology Drugs Market Size (2021-2032) & (US$ Million) Figure 32. Europe Immuno-oncology Drugs Market Size (2021-2032) & (US$ Million) Figure 33. Europe Immuno-oncology Drugs Market Share by Type (2021-2032) Figure 34. Europe Immuno-oncology Drugs Market Share by Application (2021-2032) Figure 35. Europe Immuno-oncology Drugs Market Share by Country (2021-2032) Figure 36. Germany Immuno-oncology Drugs Market Size (2021-2032) & (US$ Million) Figure 37. France Immuno-oncology Drugs Market Size (2021-2032) & (US$ Million) Figure 38. U.K. Immuno-oncology Drugs Market Size (2021-2032) & (US$ Million) Figure 39. Italy Immuno-oncology Drugs Market Size (2021-2032) & (US$ Million) Figure 40. Russia Immuno-oncology Drugs Market Size (2021-2032) & (US$ Million) Figure 41. Nordic Countries Immuno-oncology Drugs Market Size (2021-2032) & (US$ Million) Figure 42. China Immuno-oncology Drugs Market Size (2021-2032) & (US$ Million) Figure 43. China Immuno-oncology Drugs Market Share by Type (2021-2032) Figure 44. China Immuno-oncology Drugs Market Share by Application (2021-2032) Figure 45. Asia Immuno-oncology Drugs Market Size (2021-2032) & (US$ Million) Figure 46. Asia Immuno-oncology Drugs Market Share by Type (2021-2032) Figure 47. Asia Immuno-oncology Drugs Market Share by Application (2021-2032) Figure 48. Asia Immuno-oncology Drugs Market Share by Country (2021-2032) Figure 49. Japan Immuno-oncology Drugs Market Size (2021-2032) & (US$ Million) Figure 50. South Korea Immuno-oncology Drugs Market Size (2021-2032) & (US$ Million) Figure 51. Taiwan Immuno-oncology Drugs Market Size (2021-2032) & (US$ Million) Figure 52. Southeast Asia Immuno-oncology Drugs Market Size (2021-2032) & (US$ Million) Figure 53. India Immuno-oncology Drugs Market Size (2021-2032) & (US$ Million) Figure 54. Australia Immuno-oncology Drugs Market Size (2021-2032) & (US$ Million) Figure 55. South America, Middle East & Africa Immuno-oncology Drugs Market Size (2021-2032) & (US$ Million) Figure 56. South America, Middle East & Africa Immuno-oncology Drugs Market Share by Type (2021-2032) Figure 57. South America, Middle East & Africa Immuno-oncology Drugs Market Share by Application (2021-2032) Figure 58. South America, Middle East & Africa Immuno-oncology Drugs Market Share by Country (2021-2032) Figure 59. Brazil Immuno-oncology Drugs Market Size (2021-2032) & (US$ Million) Figure 60. South Africa Immuno-oncology Drugs Market Size (2021-2032) & (US$ Million) Figure 61. Saudi Arabia Immuno-oncology Drugs Market Size (2021-2032) & (US$ Million) Figure 62. Turkey Immuno-oncology Drugs Market Size (2021-2032) & (US$ Million) Figure 63. Argentina Immuno-oncology Drugs Market Size (2021-2032) & (US$ Million) Figure 64. UAE Immuno-oncology Drugs Market Size (2021-2032) & (US$ Million) Figure 65. Egypt Immuno-oncology Drugs Market Size (2021-2032) & (US$ Million) Figure 66. Chile Immuno-oncology Drugs Market Size (2021-2032) & (US$ Million) Figure 67. Research Process Figure 68. Key Executives Interviewed

Scope & coverage.

Types
  • Oncolytic Virus
  • Immune System Modulators
  • Immune Checkpoint Inhibitors
  • Cancer Vaccines
  • Others
Applications
  • Clinics
  • Hospitals
  • Community Centers
Companies covered
  • Sanofi S.A.
  • Johnson & Johnson
  • Merck & Co.
  • Lonza Group
  • Eli Lilly and Company
  • Pfizer Inc.
  • Ferring Pharmaceuticals
  • Amgen, Inc
  • AbbVie, Inc.
  • AstraZeneca, Plc
  • Spring Bank Pharmaceuticals, Inc.
  • Prometheus Therapeutics & Diagnostics
  • Novartis International AG
  • Incyte
  • ImmunoCellular Therapeutics
  • Hoffmann-La Roche AG
  • Gilead Sciences Inc.
  • Galena Biopharma
  • Enzo Biochem, Inc.
  • EMD Serono, Inc.
  • Dendreon Corporation
  • Celldex Therapeutics
  • Celgene Corporation
  • Bristol-Myers Squibb
  • Bio-Rad Laboratories, Inc.
  • Bavarian Nordic
  • Avantor, Inc.
  • Agilent Technologies Inc.
  • Agenus Inc.
  • Aduro BioTech

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Market Analysis by Type
  3. 1.2.1 Global Immuno-oncology Drugs Market Size Growth Rate by Type: 2021 VS 2025 VS 2032
  4. 1.2.2 Oncolytic Virus
  5. 1.2.3 Immune System Modulators
  6. 1.2.4 Immune Checkpoint Inhibitors
  7. 1.2.5 Cancer Vaccines
  8. 1.2.6 Others
  9. 1.3 Market Analysis by Application
  10. 1.3.1 Global Immuno-oncology Drugs Market Size Growth Rate by Application: 2021 VS 2025 VS 2032
  11. 1.3.2 Clinics
  12. 1.3.3 Hospitals
  13. 1.3.4 Community Centers
  14. 1.4 Global Market Growth Prospects
  15. 1.5 Global Immuno-oncology Drugs Growth Trends by Region
  16. 1.5.1 Global Immuno-oncology Drugs Market Size by Region: 2021 VS 2025 VS 2032
  17. 1.5.2 Immuno-oncology Drugs Market Size by Region (2021-2026)
  18. 1.5.3 Immuno-oncology Drugs Market Size by Region (2027-2032)
  19. 1.6 Assumptions and Limitations
  20. 1.7 Study Goals and Objectives
  21. 1.8 Years Considered
2 Global Immuno-oncology Drugs Market Dynamics
  1. 2.1 Immuno-oncology Drugs Industry Trends
  2. 2.2 Immuno-oncology Drugs Industry Drivers
  3. 2.3 Immuno-oncology Drugs Industry Opportunities and Challenges
  4. 2.4 Immuno-oncology Drugs Industry Restraints
3 Competitive Landscape by Company
  1. 3.1 Global Immuno-oncology Drugs Revenue by Company (2021-2026)
  2. 3.2 Global Immuno-oncology Drugs Players Revenue Ranking, 2024 VS 2025 VS 2026
  3. 3.3 Global Immuno-oncology Drugs Key Company Head office and Area Served
  4. 3.4 Global Immuno-oncology Drugs Company, Product Type & Application
  5. 3.5 Global Immuno-oncology Drugs Company Establishment Date
  6. 3.6 Market Competitive Analysis
  7. 3.6.1 Global Immuno-oncology Drugs Market CR5 and HHI
  8. 3.6.2 Global Top 5 and 10 Immuno-oncology Drugs Players Market Share by Revenue in 2025
  9. 3.6.3 2025 Immuno-oncology Drugs Tier 1, Tier 2, and Tier 3
4 Immuno-oncology Drugs Market by Type
  1. 4.1 Global Immuno-oncology Drugs Market Size by Type (2021 VS 2025 VS 2032)
  2. 4.2 Global Immuno-oncology Drugs Market Size by Type (2021-2032)
  3. 4.3 Global Immuno-oncology Drugs Market Size Share by Type (2021-2032)
5 Immuno-oncology Drugs Market by Application
  1. 5.1 Global Immuno-oncology Drugs Market Size by Application (2021 VS 2025 VS 2032)
  2. 5.2 Global Immuno-oncology Drugs Market Size by Application (2021-2032)
  3. 5.3 Global Immuno-oncology Drugs Market Size Share by Application (2021-2032)
6 Company Profiles
  1. 6.1 Sanofi S.A.
  2. 6.1.1 Sanofi S.A. Company Information
  3. 6.1.2 Sanofi S.A. Business Overview
  4. 6.1.3 Sanofi S.A. Immuno-oncology Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
  5. 6.1.4 Sanofi S.A. Immuno-oncology Drugs Product Portfolio
  6. 6.1.5 Sanofi S.A. Recent Developments
  7. 6.2 Johnson & Johnson
  8. 6.2.1 Johnson & Johnson Company Information
  9. 6.2.2 Johnson & Johnson Business Overview
  10. 6.2.3 Johnson & Johnson Immuno-oncology Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
  11. 6.2.4 Johnson & Johnson Immuno-oncology Drugs Product Portfolio
  12. 6.2.5 Johnson & Johnson Recent Developments
  13. 6.3 Merck & Co.
  14. 6.3.1 Merck & Co. Company Information
  15. 6.3.2 Merck & Co. Business Overview
  16. 6.3.3 Merck & Co. Immuno-oncology Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
  17. 6.3.4 Merck & Co. Immuno-oncology Drugs Product Portfolio
  18. 6.3.5 Merck & Co. Recent Developments
  19. 6.4 Lonza Group
  20. 6.4.1 Lonza Group Company Information
  21. 6.4.2 Lonza Group Business Overview
  22. 6.4.3 Lonza Group Immuno-oncology Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
  23. 6.4.4 Lonza Group Immuno-oncology Drugs Product Portfolio
  24. 6.4.5 Lonza Group Recent Developments
  25. 6.5 Eli Lilly and Company
  26. 6.5.1 Eli Lilly and Company Company Information
  27. 6.5.2 Eli Lilly and Company Business Overview
  28. 6.5.3 Eli Lilly and Company Immuno-oncology Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
  29. 6.5.4 Eli Lilly and Company Immuno-oncology Drugs Product Portfolio
  30. 6.5.5 Eli Lilly and Company Recent Developments
  31. 6.6 Pfizer Inc.
  32. 6.6.1 Pfizer Inc. Company Information
  33. 6.6.2 Pfizer Inc. Business Overview
  34. 6.6.3 Pfizer Inc. Immuno-oncology Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
  35. 6.6.4 Pfizer Inc. Immuno-oncology Drugs Product Portfolio
  36. 6.6.5 Pfizer Inc. Recent Developments
  37. 6.7 Ferring Pharmaceuticals
  38. 6.7.1 Ferring Pharmaceuticals Company Information
  39. 6.7.2 Ferring Pharmaceuticals Business Overview
  40. 6.7.3 Ferring Pharmaceuticals Immuno-oncology Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
  41. 6.7.4 Ferring Pharmaceuticals Immuno-oncology Drugs Product Portfolio
  42. 6.7.5 Ferring Pharmaceuticals Recent Developments
  43. 6.8 Amgen, Inc
  44. 6.8.1 Amgen, Inc Company Information
  45. 6.8.2 Amgen, Inc Business Overview
  46. 6.8.3 Amgen, Inc Immuno-oncology Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
  47. 6.8.4 Amgen, Inc Immuno-oncology Drugs Product Portfolio
  48. 6.8.5 Amgen, Inc Recent Developments
  49. 6.9 AbbVie, Inc.
  50. 6.9.1 AbbVie, Inc. Company Information
  51. 6.9.2 AbbVie, Inc. Business Overview
  52. 6.9.3 AbbVie, Inc. Immuno-oncology Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
  53. 6.9.4 AbbVie, Inc. Immuno-oncology Drugs Product Portfolio
  54. 6.9.5 AbbVie, Inc. Recent Developments
  55. 6.10 AstraZeneca, Plc
  56. 6.10.1 AstraZeneca, Plc Company Information
  57. 6.10.2 AstraZeneca, Plc Business Overview
  58. 6.10.3 AstraZeneca, Plc Immuno-oncology Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
  59. 6.10.4 AstraZeneca, Plc Immuno-oncology Drugs Product Portfolio
  60. 6.10.5 AstraZeneca, Plc Recent Developments
  61. 6.11 Spring Bank Pharmaceuticals, Inc.
  62. 6.11.1 Spring Bank Pharmaceuticals, Inc. Company Information
  63. 6.11.2 Spring Bank Pharmaceuticals, Inc. Business Overview
  64. 6.11.3 Spring Bank Pharmaceuticals, Inc. Immuno-oncology Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
  65. 6.11.4 Spring Bank Pharmaceuticals, Inc. Immuno-oncology Drugs Product Portfolio
  66. 6.11.5 Spring Bank Pharmaceuticals, Inc. Recent Developments
  67. 6.12 Prometheus Therapeutics & Diagnostics
  68. 6.12.1 Prometheus Therapeutics & Diagnostics Company Information
  69. 6.12.2 Prometheus Therapeutics & Diagnostics Business Overview
  70. 6.12.3 Prometheus Therapeutics & Diagnostics Immuno-oncology Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
  71. 6.12.4 Prometheus Therapeutics & Diagnostics Immuno-oncology Drugs Product Portfolio
  72. 6.12.5 Prometheus Therapeutics & Diagnostics Recent Developments
  73. 6.13 Novartis International AG
  74. 6.13.1 Novartis International AG Company Information
  75. 6.13.2 Novartis International AG Business Overview
  76. 6.13.3 Novartis International AG Immuno-oncology Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
  77. 6.13.4 Novartis International AG Immuno-oncology Drugs Product Portfolio
  78. 6.13.5 Novartis International AG Recent Developments
  79. 6.14 Incyte
  80. 6.14.1 Incyte Company Information
  81. 6.14.2 Incyte Business Overview
  82. 6.14.3 Incyte Immuno-oncology Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
  83. 6.14.4 Incyte Immuno-oncology Drugs Product Portfolio
  84. 6.14.5 Incyte Recent Developments
  85. 6.15 ImmunoCellular Therapeutics
  86. 6.15.1 ImmunoCellular Therapeutics Company Information
  87. 6.15.2 ImmunoCellular Therapeutics Business Overview
  88. 6.15.3 ImmunoCellular Therapeutics Immuno-oncology Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
  89. 6.15.4 ImmunoCellular Therapeutics Immuno-oncology Drugs Product Portfolio
  90. 6.15.5 ImmunoCellular Therapeutics Recent Developments
  91. 6.16 Hoffmann-La Roche AG
  92. 6.16.1 Hoffmann-La Roche AG Company Information
  93. 6.16.2 Hoffmann-La Roche AG Business Overview
  94. 6.16.3 Hoffmann-La Roche AG Immuno-oncology Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
  95. 6.16.4 Hoffmann-La Roche AG Immuno-oncology Drugs Product Portfolio
  96. 6.16.5 Hoffmann-La Roche AG Recent Developments
  97. 6.17 Gilead Sciences Inc.
  98. 6.17.1 Gilead Sciences Inc. Company Information
  99. 6.17.2 Gilead Sciences Inc. Business Overview
  100. 6.17.3 Gilead Sciences Inc. Immuno-oncology Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
  101. 6.17.4 Gilead Sciences Inc. Immuno-oncology Drugs Product Portfolio
  102. 6.17.5 Gilead Sciences Inc. Recent Developments
  103. 6.18 Galena Biopharma
  104. 6.18.1 Galena Biopharma Company Information
  105. 6.18.2 Galena Biopharma Business Overview
  106. 6.18.3 Galena Biopharma Immuno-oncology Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
  107. 6.18.4 Galena Biopharma Immuno-oncology Drugs Product Portfolio
  108. 6.18.5 Galena Biopharma Recent Developments
  109. 6.19 Enzo Biochem, Inc.
  110. 6.19.1 Enzo Biochem, Inc. Company Information
  111. 6.19.2 Enzo Biochem, Inc. Business Overview
  112. 6.19.3 Enzo Biochem, Inc. Immuno-oncology Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
  113. 6.19.4 Enzo Biochem, Inc. Immuno-oncology Drugs Product Portfolio
  114. 6.19.5 Enzo Biochem, Inc. Recent Developments
  115. 6.20 EMD Serono, Inc.
  116. 6.20.1 EMD Serono, Inc. Company Information
  117. 6.20.2 EMD Serono, Inc. Business Overview
  118. 6.20.3 EMD Serono, Inc. Immuno-oncology Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
  119. 6.20.4 EMD Serono, Inc. Immuno-oncology Drugs Product Portfolio
  120. 6.20.5 EMD Serono, Inc. Recent Developments
  121. 6.21 Dendreon Corporation
  122. 6.21.1 Dendreon Corporation Company Information
  123. 6.21.2 Dendreon Corporation Business Overview
  124. 6.21.3 Dendreon Corporation Immuno-oncology Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
  125. 6.21.4 Dendreon Corporation Immuno-oncology Drugs Product Portfolio
  126. 6.21.5 Dendreon Corporation Recent Developments
  127. 6.22 Celldex Therapeutics
  128. 6.22.1 Celldex Therapeutics Company Information
  129. 6.22.2 Celldex Therapeutics Business Overview
  130. 6.22.3 Celldex Therapeutics Immuno-oncology Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
  131. 6.22.4 Celldex Therapeutics Immuno-oncology Drugs Product Portfolio
  132. 6.22.5 Celldex Therapeutics Recent Developments
  133. 6.23 Celgene Corporation
  134. 6.23.1 Celgene Corporation Company Information
  135. 6.23.2 Celgene Corporation Business Overview
  136. 6.23.3 Celgene Corporation Immuno-oncology Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
  137. 6.23.4 Celgene Corporation Immuno-oncology Drugs Product Portfolio
  138. 6.23.5 Celgene Corporation Recent Developments
  139. 6.24 Bristol-Myers Squibb
  140. 6.24.1 Bristol-Myers Squibb Company Information
  141. 6.24.2 Bristol-Myers Squibb Business Overview
  142. 6.24.3 Bristol-Myers Squibb Immuno-oncology Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
  143. 6.24.4 Bristol-Myers Squibb Immuno-oncology Drugs Product Portfolio
  144. 6.24.5 Bristol-Myers Squibb Recent Developments
  145. 6.25 Bio-Rad Laboratories, Inc.
  146. 6.25.1 Bio-Rad Laboratories, Inc. Company Information
  147. 6.25.2 Bio-Rad Laboratories, Inc. Business Overview
  148. 6.25.3 Bio-Rad Laboratories, Inc. Immuno-oncology Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
  149. 6.25.4 Bio-Rad Laboratories, Inc. Immuno-oncology Drugs Product Portfolio
  150. 6.25.5 Bio-Rad Laboratories, Inc. Recent Developments
  151. 6.26 Bavarian Nordic
  152. 6.26.1 Bavarian Nordic Company Information
  153. 6.26.2 Bavarian Nordic Business Overview
  154. 6.26.3 Bavarian Nordic Immuno-oncology Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
  155. 6.26.4 Bavarian Nordic Immuno-oncology Drugs Product Portfolio
  156. 6.26.5 Bavarian Nordic Recent Developments
  157. 6.27 Avantor, Inc.
  158. 6.27.1 Avantor, Inc. Company Information
  159. 6.27.2 Avantor, Inc. Business Overview
  160. 6.27.3 Avantor, Inc. Immuno-oncology Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
  161. 6.27.4 Avantor, Inc. Immuno-oncology Drugs Product Portfolio
  162. 6.27.5 Avantor, Inc. Recent Developments
  163. 6.28 Agilent Technologies Inc.
  164. 6.28.1 Agilent Technologies Inc. Company Information
  165. 6.28.2 Agilent Technologies Inc. Business Overview
  166. 6.28.3 Agilent Technologies Inc. Immuno-oncology Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
  167. 6.28.4 Agilent Technologies Inc. Immuno-oncology Drugs Product Portfolio
  168. 6.28.5 Agilent Technologies Inc. Recent Developments
  169. 6.29 Agenus Inc.
  170. 6.29.1 Agenus Inc. Company Information
  171. 6.29.2 Agenus Inc. Business Overview
  172. 6.29.3 Agenus Inc. Immuno-oncology Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
  173. 6.29.4 Agenus Inc. Immuno-oncology Drugs Product Portfolio
  174. 6.29.5 Agenus Inc. Recent Developments
  175. 6.30 Aduro BioTech
  176. 6.30.1 Aduro BioTech Company Information
  177. 6.30.2 Aduro BioTech Business Overview
  178. 6.30.3 Aduro BioTech Immuno-oncology Drugs Revenue and Gross Margin (US$ Million) & (2021-2026)
  179. 6.30.4 Aduro BioTech Immuno-oncology Drugs Product Portfolio
  180. 6.30.5 Aduro BioTech Recent Developments
7 North America
  1. 7.1 North America Immuno-oncology Drugs Market Size (2021-2032)
  2. 7.2 North America Immuno-oncology Drugs Market Size by Type
  3. 7.2.1 North America Immuno-oncology Drugs Market Size by Type (2021-2026)
  4. 7.2.2 North America Immuno-oncology Drugs Market Size by Type (2027-2032)
  5. 7.2.3 North America Immuno-oncology Drugs Market Share by Type (2021-2032)
  6. 7.3 North America Immuno-oncology Drugs Market Size by Application
  7. 7.3.1 North America Immuno-oncology Drugs Market Size by Application (2021-2026)
  8. 7.3.2 North America Immuno-oncology Drugs Market Size by Application (2027-2032)
  9. 7.3.3 North America Immuno-oncology Drugs Market Share by Application (2021-2032)
  10. 7.4 North America Immuno-oncology Drugs Market Size by Country
  11. 7.4.1 North America Immuno-oncology Drugs Market Size by Country (2021 VS 2025 VS 2032)
  12. 7.4.2 North America Immuno-oncology Drugs Market Size by Country (2021-2026)
  13. 7.4.3 North America Immuno-oncology Drugs Market Size by Country (2027-2032)
  14. 7.4.4 North America Immuno-oncology Drugs Market Share by Country (2021-2032)
  15. 7.4.5 United States
  16. 7.4.6 Canada
  17. 7.4.7 Mexico
8 Europe
  1. 8.1 Europe Immuno-oncology Drugs Market Size (2021-2032)
  2. 8.2 Europe Immuno-oncology Drugs Market Size by Type
  3. 8.2.1 Europe Immuno-oncology Drugs Market Size by Type (2021-2026)
  4. 8.2.2 Europe Immuno-oncology Drugs Market Size by Type (2027-2032)
  5. 8.2.3 Europe Immuno-oncology Drugs Market Share by Type (2021-2032)
  6. 8.3 Europe Immuno-oncology Drugs Market Size by Application
  7. 8.3.1 Europe Immuno-oncology Drugs Market Size by Application (2021-2026)
  8. 8.3.2 Europe Immuno-oncology Drugs Market Size by Application (2027-2032)
  9. 8.3.3 Europe Immuno-oncology Drugs Market Share by Application (2021-2032)
  10. 8.4 Europe Immuno-oncology Drugs Market Size by Country
  11. 8.4.1 Europe Immuno-oncology Drugs Market Size by Country (2021 VS 2025 VS 2032)
  12. 8.4.2 Europe Immuno-oncology Drugs Market Size by Country (2021-2026)
  13. 8.4.3 Europe Immuno-oncology Drugs Market Size by Country (2027-2032)
  14. 8.4.4 Europe Immuno-oncology Drugs Market Share by Country (2021-2032)
  15. 8.4.5 Germany
  16. 8.4.6 France
  17. 8.4.7 U.K.
  18. 8.4.8 Italy
  19. 8.4.9 Russia
  20. 8.4.10 Nordic Countries
9 China
  1. 9.1 China Immuno-oncology Drugs Market Size (2021-2032)
  2. 9.2 China Immuno-oncology Drugs Market Size by Type
  3. 9.2.1 China Immuno-oncology Drugs Market Size by Type (2021-2026)
  4. 9.2.2 China Immuno-oncology Drugs Market Size by Type (2027-2032)
  5. 9.2.3 China Immuno-oncology Drugs Market Share by Type (2021-2032)
  6. 9.3 China Immuno-oncology Drugs Market Size by Application
  7. 9.3.1 China Immuno-oncology Drugs Market Size by Application (2021-2026)
  8. 9.3.2 China Immuno-oncology Drugs Market Size by Application (2027-2032)
  9. 9.3.3 China Immuno-oncology Drugs Market Share by Application (2021-2032)
10 Asia (Excluding China)
  1. 10.1 Asia Immuno-oncology Drugs Market Size (2021-2032)
  2. 10.2 Asia Immuno-oncology Drugs Market Size by Type
  3. 10.2.1 Asia Immuno-oncology Drugs Market Size by Type (2021-2026)
  4. 10.2.2 Asia Immuno-oncology Drugs Market Size by Type (2027-2032)
  5. 10.2.3 Asia Immuno-oncology Drugs Market Share by Type (2021-2032)
  6. 10.3 Asia Immuno-oncology Drugs Market Size by Application
  7. 10.3.1 Asia Immuno-oncology Drugs Market Size by Application (2021-2026)
  8. 10.3.2 Asia Immuno-oncology Drugs Market Size by Application (2027-2032)
  9. 10.3.3 Asia Immuno-oncology Drugs Market Share by Application (2021-2032)
  10. 10.4 Asia Immuno-oncology Drugs Market Size by Country
  11. 10.4.1 Asia Immuno-oncology Drugs Market Size by Country (2021 VS 2025 VS 2032)
  12. 10.4.2 Asia Immuno-oncology Drugs Market Size by Country (2021-2026)
  13. 10.4.3 Asia Immuno-oncology Drugs Market Size by Country (2027-2032)
  14. 10.4.4 Asia Immuno-oncology Drugs Market Share by Country (2021-2032)
  15. 10.4.5 Japan
  16. 10.4.6 South Korea
  17. 10.4.7 Taiwan
  18. 10.4.8 Southeast Asia
  19. 10.4.9 India
  20. 10.4.10 Australia
11 South America, Middle East & Africa
  1. 11.1 South America, Middle East & Africa Immuno-oncology Drugs Market Size (2021-2032)
  2. 11.2 South America, Middle East & Africa Immuno-oncology Drugs Market Size by Type
  3. 11.2.1 South America, Middle East & Africa Immuno-oncology Drugs Market Size by Type (2021-2026)
  4. 11.2.2 South America, Middle East & Africa Immuno-oncology Drugs Market Size by Type (2027-2032)
  5. 11.2.3 South America, Middle East & Africa Immuno-oncology Drugs Market Share by Type (2021-2032)
  6. 11.3 South America, Middle East & Africa Immuno-oncology Drugs Market Size by Application
  7. 11.3.1 South America, Middle East & Africa Immuno-oncology Drugs Market Size by Application (2021-2026)
  8. 11.3.2 South America, Middle East & Africa Immuno-oncology Drugs Market Size by Application (2027-2032)
  9. 11.3.3 South America, Middle East & Africa Immuno-oncology Drugs Market Share by Application (2021-2032)
  10. 11.4 South America, Middle East & Africa Immuno-oncology Drugs Market Size by Country
  11. 11.4.1 South America, Middle East & Africa Immuno-oncology Drugs Market Size by Country (2021 VS 2025 VS 2032)
  12. 11.4.2 South America, Middle East & Africa Immuno-oncology Drugs Market Size by Country (2021-2026)
  13. 11.4.3 South America, Middle East & Africa Immuno-oncology Drugs Market Size by Country (2027-2032)
  14. 11.4.4 South America, Middle East & Africa Immuno-oncology Drugs Market Share by Country (2021-2032)
  15. 11.4.5 Brazil
  16. 11.4.6 South Africa
  17. 11.4.7 Saudi Arabia
  18. 11.4.8 Turkey
  19. 11.4.9 Argentina
  20. 11.4.9 UAE
  21. 11.4.9 Egypt
  22. 11.4.9 Chile
12 Concluding Insights
    13 Appendix
    1. 13.1 Reasons for Doing This Study
    2. 13.2 Research Methodology
    3. 13.3 Research Process
    4. 13.4 Authors List of This Report
    5. 13.5 Data Source
    6. 13.5.1 Secondary Sources
    7. 13.5.2 Primary Sources
    8. 13.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst